Department of Physiology, Radboud University Nijmegen Medical Centre, The Netherlands.
Magnes Res. 2011 Sep;24(3):S101-8. doi: 10.1684/mrh.2011.0289.
In healthy individuals, Mg(2+) homeostasis is tightly regulated by the concerted action of intestinal absorption, exchange with bone, and renal excretion. The kidney, more precisely the distal convoluted tubule (DCT), is the final determinant of plasma Mg(2+) concentrations. Positional cloning strategies in families with hereditary hypomagnesemia identified defects in several proteins localized in the DCT as causative factors. So far, the identified actors involved in Mg(2+) handling in the DCT include: the transient receptor potential channel melastatin member 6, the pro-epidermal growth factor, the thiazide-sensitive Na(+)-Cl(-) cotransporter, the γ-subunit of the Na(+)/K(+)-ATPase, the hepatocyte nuclear factor 1B, the potassium channels Kv1.1 and Kir4.1, and the cyclin M2. In the years to come, the identification of new magnesiotropic genes and related proteins will further clarify the role of the kidney in Mg(2+) homeostasis, and will potentially lead to new therapeutic approaches for hypomagnesemia.
在健康个体中,Mg(2+)的体内平衡受肠道吸收、与骨骼交换以及肾脏排泄的协同作用严格调控。肾脏,更确切地说是远曲小管(DCT),是决定血浆 Mg(2+)浓度的最终决定因素。在遗传性低镁血症的家族中,通过定位克隆策略确定了几种定位于 DCT 的蛋白缺陷是致病因素。迄今为止,在 DCT 中参与 Mg(2+)处理的已鉴定出的作用因子包括:瞬时受体电位通道 melastatin 成员 6、前表皮生长因子、噻嗪类敏感的 Na(+)-Cl(-)共转运体、Na(+)/K(+)-ATP 酶的γ亚基、肝细胞核因子 1B、钾通道 Kv1.1 和 Kir4.1 以及细胞周期蛋白 M2。在未来的几年中,新的镁转运基因和相关蛋白的鉴定将进一步阐明肾脏在 Mg(2+)体内平衡中的作用,并可能为低镁血症提供新的治疗方法。